Crystalline Forms of sGC Stimulator for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for crystalline forms of the sGC stimulator 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine that are stable and suitable for effective delivery in pharmaceutical applications.
Innovation Solution
The development of novel crystalline forms, including Form A, Form B, Hydrate 1, Hydrate 2, Hydrate 3, ethanol solvate, methanol solvate, methyl ethyl ketone solvate, dichloromethane solvate, and acetonitrile solvate, which provide enhanced stability and suitability for pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If amorphous or non-crystalline forms of the sGC stimulator are used, then the compound can be easily prepared, but the stability and suitability for pharmaceutical delivery are insufficient
Solution Approach 1:
The patent applies parameter changes by transforming the physical state of the sGC stimulator compound from amorphous to crystalline forms. This phase transition fundamentally alters the molecular arrangement and intermolecular interactions, thereby enhancing stability while maintaining pharmaceutical manufacturability through established crystallization techniques.
Solution Approach 2:
The invention directly employs phase transitions by developing multiple crystalline polymorphs (Form A, Form B, hydrates, and solvates) of the sGC stimulator. These phase transitions from amorphous to ordered crystalline structures improve stability, solubility, and bioavailability while allowing for scalable pharmaceutical manufacturing through controlled crystallization processes.
2Reliability
If multiple crystalline forms are developed, then stability and pharmacokinetic properties are improved, but the complexity of the patent and selection process increases
Solution Approach 1:
The patent applies segmentation by dividing the crystalline forms into distinct categories: anhydrous polymorphs (Form A, Form B), hydrates (Hydrate 1, Hydrate 2, Hydrate 3), and solvates (ethanol, methanol, methyl ethyl ketone, dichloromethane, acetonitrile). Each segment has specific characteristics optimized for different pharmaceutical applications, allowing systematic selection based on required properties.
Solution Approach 2:
The multiple crystalline forms serve universal pharmaceutical needs by providing options for different delivery routes, storage conditions, and therapeutic indications. Each crystalline form maintains the core sGC stimulator activity while offering differentiated properties for solubility, stability, and bioavailability, making the patent broadly applicable across various pharmaceutical formulations.
Data Source
AI summary
The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, depicted below as a compound of Formula (I):which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.